Speaker:

Educational Objectives:
•    Assess the clinical and economic burden of HAE, including treatment costs, healthcare utilization, and the impact of disease management strategies on patient outcomes.
• Differentiate the efficacy, safety, and administration of established and emerging prophylactic therapies for HAE to optimize treatment selection.
• Examine the latest advancements in on-demand treatment options for HAE and their role in reducing attack severity, frequency, and healthcare burden.
• Explore the evolving role of managed care professionals in facilitating access to appropriate HAE therapies, supporting treatment adherence, and implementing evidence-based care strategies


Overview:
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent attacks of severe angioedema in various parts of the body. It can be triggered by stress, physical trauma, or other illnesses, with symptoms that progress over time, leading to significant morbidity and mortality if left untreated. Diagnostic challenges often lead to misdiagnosis, delayed diagnosis, and ineffective treatment. Participants will gain insight into the burden of disease, current treatment strategies for prophylaxis and acute attacks, and the latest clinical guidelines and recommendations. A significant focus will be placed on new and emerging therapies, individualized treatment considerations, and the economic impact of HAE, including access barriers and real-world evidence. The activity will address essential treatment considerations from the managed care perspective, including individualizing treatment plans based on disease severity, symptom variability, patient preferences, and the route of administration, whether for on-demand or prophylactic therapies. The substantial economic burden of HAE, encompassing direct and indirect costs, will also be discussed to effectively guide formulary management, prior authorization processes, and support for individual treatment plans.
 
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.


Activity Disclaimer